The ZOMAXX I trial tested the noninferiority of a zotarolimus-eluting coronary stent ( ZoMaxx ( ) ) when compared with a paclitaxel-eluting coronary stent ( Taxus ( ) Express ( 2 ) ) in a randomized trial of percutaneous intervention for de novo coronary artery stenosis .
